All In Biotech

Free tool

FAERS Monitor: Combogesic

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209471 or its brand name (Combogesic, Acetaminophen, Ibuprofen). Reports on generic versions are filed under their own applications.

Reports

219

Serious

18

8% of reports

Hospitalization

7

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective47
  • drug effective for unapproved indication30
  • therapeutic product effect incomplete27
  • drug effect less than expected15
  • underdose13
  • overdose10
  • incorrect dose administered9
  • drug ineffective for unapproved indication8
  • hypersensitivity8
  • off label use7
  • inappropriate schedule of product administration6
  • drug hypersensitivity5
  • malaise4
  • somnolence4
  • diarrhoea3

Reports by year received

View as table
YearReports
20211
2023108
202455
202543
202612

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,940 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug effective for unapproved indicationSignal3098.570.62,799
drug effect less than expectedSignal1597.359.71,335
therapeutic product effect incompleteSignal2736.525.6899
underdoseSignal1317.110.1182
drug ineffective for unapproved indicationSignal814.07.184
overdoseSignal104.52.424
hypersensitivitySignal84.12.116
incorrect dose administeredSignal93.82.016
drug ineffectiveSignal473.42.784
inappropriate schedule of product administrationSignal63.21.57
drug hypersensitivity52.51.03
somnolence41.90.71
malaise40.90.30
off label use70.80.40
diarrhoea30.40.12

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.